CYBN cybin.com: Multiplikator Forward P/S

Cybin Inc. is implementing advanced psychedelic therapy methods to combat depression. The business valuation is based on patents, the success of which is determined by regulatory decisions. The company is striving for pricing power through its unique, fast-acting CYB003 molecule. The projected P/S level on the GURU.Markets terminal analytical chart reflects market expectations, where describes the current status of the metric.

CYBN (Cybin) riwayat Rasio kapitalisasi pasar marang pendapatan mangsa ngarep saka 04.07.2022 nganti 13.11.2026

Rincian analitis perusahaan Cybin Inc.

- rega pasar lan target rega analis:

Bagan rega Cybin|CYBN - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Cybin Inc.|CYBN - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Cybin|CYBN - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku cybin.com|CYBN - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

- indikator pendapatan resik lan kelipatan nilai:

CYBN - Bathi perusahaan|Proyeksi bathi mangsa ngarep Cybin Inc.|CYBN - Koefisien rega marang bathi|Prakiraan rega marang bathi Cybin|CYBN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Cybin Inc.|CYBN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Cybin|CYBN - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan cybin.com|CYBN - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cybin Inc.

- rincian pendapatan lan dodolan:

CYBN - Volume dodolan perusahaan|Prakiraan pendapatan perusahaan Cybin|CYBN - Rasio rega marang dodolan|Multiplikator Forward P/S Cybin Inc.

Pambiji fundamental perusahaan:Cybin Corp (CYBN)

Cybin Inc. is currently in an intensive development phase for breakthrough psilocybin-based drugs, making its valuation highly dependent on the future success of its pipeline. The business's forward P/S reflects the ratio of current market capitalization to expected annual revenue, allowing investors to promptly identify shifts in fundamental trends via market expectations analysis before official reports are published.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|atai Life Sciences Corp - Multiplikator Forward P/S|GH Research Group (GHRS) - Multiplikator forward rega marang pendapatan|MNMD (Mind Medicine) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep compasspathways.com (CMPS)|LBRX (LB Pharmaceuticals) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan DRUG|Multiplikator Forward P/S VNDA|Rasio kapitalisasi marang dodolan sing dikarepake Alto Neuroscience Corp|Rasio rega marang prakiraan pendapatan NRx Pharmaceuticals NRXP|CING: Kapitalisasi marang prakiraan pendapatan|SILO: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CPHI (China Pharma Holdings)|CMND: Multiplikator Forward P/S|PBM - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan SciSparc Ltd|Kapitalisasi marang prakiraan pendapatan SEEL (seelostherapeutics.com)|Multiplikator Forward P/S VRPX|Multiplikator forward rega marang pendapatan Karuna Therapeutics Inc KRTX